Lu Peng sold $10K of PHVS
Lu Peng (Chief Medical Officer) sold 300 shares of Pharvaris N.V. (PHVS) at $34.00 on 2026-06-18 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The only new information is the officer’s planned open-market sale details (date, shares, price, post-transaction holdings).
Market read
This is a routine insider-sale datapoint with limited trading implications absent any accompanying company catalyst.
What to watch
The filing does not disclose any change in company outlook, trial results, or financing; traders should avoid extrapolating fundamentals from a small, planned sale.
Background
The article is an SEC Form 4 insider transaction disclosure for Pharvaris N.V. (PHVS).
Ticker impact
Form 4 shows CMO Lu Peng sold 300 shares of Pharvaris N.V. at $34.00/share under a pre-arranged 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely muted and short-lived.
The filing is a scheduled open-market sale by an officer under a 10b5-1 plan, with modest disclosed value ($10.2k) and no accompanying company-specific operational/regulatory update.
Market effects
No clear sector read-through; this is an individual insider transaction without new clinical/regulatory information.
None indicated.
None indicated.
Counterpoint
Because it’s a 10b5-1 plan, the sale may be purely administrative (liquidity/tax) and should not be over-weighted as bearish.
Key entities
- issuerPharvaris N.V.
Company whose Form 4 insider sale was disclosed.
- insiderLu Peng
Chief Medical Officer who sold 300 shares under a pre-arranged 10b5-1 plan.
